title: Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia.
abstract: We report on the data collected in the Italian Registry of acquired haemophilia (AH) in 2001. Recombinant activated factor VII (rFVIIa) was selected as first-line therapy in 19 bleeding episodes because of their severity and as salvage in one case. Bleeding was controlled in 90% of the episodes, indicating the efficacy of rFVIIa in HA.
authors.forename: Francesco
authors.initials: F
authors.lastname: Baudo
authors.forename: Francesco
authors.initials: F
authors.lastname: de Cataldo
authors.forename: Gianluca
authors.initials: G
authors.lastname: Gaidano
mesh_terms: D001323:Autoantibodies; D005167:Factor VII / Q000627:therapeutic use*; D005169:Factor VIII / Q000276:immunology*; D015942:Factor VIIa; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D006470:Hemorrhage / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D007558:Italy; D011994:Recombinant Proteins / Q000627:therapeutic use; D012042:Registries
chemical_list: D001323:Autoantibodies; D011994:Recombinant Proteins; D005167:Factor VII; D005169:Factor VIII; C103587:recombinant FVIIa; D015942:Factor VIIa